Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEBORAH G NIXON

Allopathic & Osteopathic Physicians Dermatology

NPI
1073575684
CMS profile
963336
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$304.19

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $304.19 15

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $60.52 3
Amgen Inc. $56.98 2
SUN PHARMACEUTICAL INDUSTRIES INC. $56.09 2
E.R. Squibb & Sons, L.L.C. $38.54 2
STRATA Skin Sciences, Inc. $29.41 3
GENZYME CORPORATION $28.74 1
Tempus AI, Inc $20.61 1
Lilly USA, LLC $13.30 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEBORAH G NIXON

NPI 1073575684 · CMS profile ID 963336

Allopathic & Osteopathic Physicians / Dermatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073575684?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073575684?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073575684?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DEBORAH G NIXON, NPI 1073575684, CMS profile ID 963336, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1073575684?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $304.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $30.6308/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152143094 CMS
E.R. Squibb & Sons, L.L.C. $13.7208/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101661634 CMS
ABBVIE INC. $22.6307/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105129567 CMS
GENZYME CORPORATION $28.7407/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139634093 CMS
STRATA Skin Sciences, Inc. $12.9406/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146582359 CMS
E.R. Squibb & Sons, L.L.C. $24.8206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101661607 CMS
Amgen Inc. $28.7205/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117340553 CMS
Tempus AI, Inc $20.6105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150170896 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $25.4604/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152143092 CMS
ABBVIE INC. $13.2304/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105129565 CMS
Amgen Inc. $28.2603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117340551 CMS
Lilly USA, LLC $13.3003/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136138865 CMS
STRATA Skin Sciences, Inc. $6.3002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146582357 CMS
ABBVIE INC. $24.6602/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105129563 CMS
STRATA Skin Sciences, Inc. $10.1701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146582355 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $590.27 37
PY2020 $227.01 10
PY2021 $416.17 22
PY2022 $608.13 29
PY2023 $275.09 10
PY2024 $304.19 15
PY2025 $1,096.15 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $296,458.78 66
PY2024 Principal investigator $247,116.67 29
PY2023 Principal investigator $166,737.83 35
PY2022 Recipient $123.00 1
PY2022 Principal investigator $34,841.75 6
PY2021 Principal investigator $52,302.21 8
PY2020 Recipient $2,108.59 2
PY2020 Principal investigator $97,200.02 2
PY2019 Recipient $39,789.75 2
PY2019 Principal investigator $7,564.30 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,084.85 12/31/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228747939
Principal investigator 1 PFIZER INC. $1,913.80 12/17/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228747341
Principal investigator 1 PFIZER INC. $7,199.40 12/17/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749981
Principal investigator 1 PFIZER INC. $7,319.10 12/16/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228746746
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,096.75 12/12/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431570
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,094.94 12/04/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431566
Principal investigator 1 PFIZER INC. $1,312.35 12/03/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228747568
Principal investigator 1 PFIZER INC. $1,084.85 11/26/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730328
Principal investigator 1 PFIZER INC. $2,462.85 11/25/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228737547
Principal investigator 1 PFIZER INC. $4,771.90 11/18/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228738125
Principal investigator 1 PFIZER INC. $2,462.85 11/05/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730417
Principal investigator 1 PFIZER INC. $1,084.85 10/29/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228742288
Principal investigator 1 PFIZER INC. $2,192.40 10/22/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228722718
Principal investigator 1 PFIZER INC. $1,745.10 10/11/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228757222
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $58.75 10/10/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431560
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,936.56 10/10/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431562
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431542
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431544
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $400.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431546
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $300.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431548
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $100.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431550
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $577.50 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431552
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $425.00 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431554
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $58.75 10/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431556
Principal investigator 1 PFIZER INC. $1,084.85 10/04/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741233
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,882.38 09/25/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431538
Principal investigator 1 PFIZER INC. $4,816.35 09/24/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228748581
Principal investigator 1 PFIZER INC. $2,243.80 09/19/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228758789
Principal investigator 1 Eli Lilly and Company $2,400.00 09/12/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187879959
Principal investigator 1 PFIZER INC. $957.45 09/12/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228752062
Principal investigator 1 PFIZER INC. $250.00 09/10/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228760021
Principal investigator 1 Amgen Inc. $8,528.00 08/23/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640825
Principal investigator 1 PFIZER INC. $6,048.25 08/23/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228767583
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,158.38 08/20/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431534
Principal investigator 1 PFIZER INC. $3,026.80 08/09/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228788517
Principal investigator 1 PFIZER INC. $2,265.25 08/05/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228767056
Principal investigator 1 PFIZER INC. $4,355.24 07/29/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228763823
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,183.06 07/18/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431524
Principal investigator 1 PFIZER INC. $4,366.32 07/17/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228786292
Principal investigator 1 Eli Lilly and Company $3,325.00 07/07/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187882364
Principal investigator 1 PFIZER INC. $1,913.80 07/02/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228782453
Principal investigator 1 PFIZER INC. $957.45 07/02/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228792720
Principal investigator 1 PFIZER INC. $4,771.90 06/26/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228791718
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,494.19 06/18/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431520
Principal investigator 1 Amgen Inc. $8,900.00 06/04/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246640823
Principal investigator 1 PFIZER INC. $1,158.95 05/30/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764245
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,733.25 05/27/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431516
Principal investigator 1 PFIZER INC. $3,933.35 05/16/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228763485
Principal investigator 1 PFIZER INC. $19,440.00 05/06/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228723398
Principal investigator 1 PFIZER INC. $5,525.27 05/03/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228784189
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,546.56 04/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431514
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,246.50 03/24/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431508
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,465.00 03/21/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431504
Principal investigator 1 PFIZER INC. $1,084.85 03/06/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228782773
Principal investigator 1 PFIZER INC. $2,042.30 03/04/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228797372
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,226.19 03/03/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431500
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 02/19/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431498
Principal investigator 1 PFIZER INC. $8,989.57 02/11/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751716
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,207.75 02/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431494
Principal investigator 1 Eli Lilly and Company $64,098.22 02/05/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187883650
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $400.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431470
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431472
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $100.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431474
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431476
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431478
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $350.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431480